#Canada #Toronto #Canaccord Genuity #Cardiol Therapeutics #heart disease therapies

Cardiol Therapeutics to Engage in a Live Fireside Chat

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), a prominent late-stage life sciences company, is gearing up to take part in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference. This notable event is scheduled for August 11, 2026, at 9:00 a.m. EDT and will be held at the InterContinental Boston Hotel in Boston, Massachusetts. With a focus on advancing innovative anti-inflammatory and anti-fibrotic therapies for heart disease, Cardiol's participation is set to shed light on its groundbreaking developments in this vital area of medical research.

The Fireside Chat will be available for viewing through a live webcast, which can be accessed in the 'Events & Presentations' section of Cardiol’s investor relations website. This event offers investors and stakeholders a unique opportunity to hear directly from company executives about their strategic vision and ongoing clinical programs.

About Cardiol Therapeutics

Cardiol Therapeutics is at the forefront of developing therapies aimed at addressing heart disease—one of the leading global health challenges. The company's flagship product, CardiolRx™, is a novel small-molecule drug candidate that effectively modulates the inflammasome pathway activation, an integral part of the innate immune system. This pathway is crucial in managing inflammation and fibrosis associated with various cardiac conditions, including pericarditis, myocarditis, and heart failure.

Ongoing Clinical Programs

Cardiol Therapeutics is actively engaged in a couple of significant clinical programs. The MAVERIC program investigates the efficacy of CardiolRx™ specifically for the treatment of recurrent pericarditis, a condition characterized by severe chest pain and distressing symptoms that often necessitate emergency medical care. Within this framework, the Phase II MAvERIC-Pilot study has been successfully completed, and the pivotal Phase III MAVERIC trial is currently in progress. Notably, the U.S. FDA has recognized CardiolRx™ with Orphan Drug Designation for treating recurrent pericarditis, underscoring its potential impact on patient health.

Additionally, the ARCHER program evaluates the implications of CardiolRx™ for treating acute myocarditis, a serious condition that can lead to sudden cardiac death in young individuals. This program includes the completed Phase II ARCHER study, which assessed the safety, tolerability, and efficacy of CardiolRx™ among affected patient populations.

Beyond these initiatives, Cardiol Therapeutics is also innovating with CRD-38, a novel drug formulation administered subcutaneously, targeting inflammatory heart diseases. With the increasing burden of heart failure leading to significant health expenditures in the U.S. estimated at over $30 billion annually, the development of effective treatments such as CRD-38 stands as a vital step forward.

Looking Ahead

As Cardiol Therapeutics prepares to present at the Canaccord Genuity Annual Growth Conference, the company is focused not only on sharing its progress but also on engaging with potential investors and stakeholders interested in the future of heart disease therapeutics. Participants in the Fireside Chat can expect an insightful discussion about the company's strategic objectives, upcoming trials, and how it plans to cement its role as a leader in the biopharmaceutical industry, dedicated to enhancing patient outcomes in cardiovascular health.

For those seeking additional information on Cardiol Therapeutics and its initiatives, please visit Cardiol's website.

A Note on Forward-Looking Statements

Investors are reminded that this announcement contains forward-looking information regarding the company’s plans and activities concerning its drug development and clinical trials. As such, caution should be exercised when interpreting these projections, as various risks and uncertainties could impact actual results as stated. Further details are available in Cardiol's filings with the Canadian Securities Administrators and the U.S. Securities and Exchange Commission.

Engagement in discussions centered on heart disease therapies is essential as these innovations hold the potential to redefine patient care and quality of life for individuals grappling with daunting cardiovascular issues.